Published data regarding the efficacy of aripiprazole in the treatment of schizophrenia indicate superiority to placebo and comparability to risperidone, in Positive and Negative Syndrome Scale (PANSS) total and Clinical Global Impression of Severity (CGI-S) improvement scores. In these studies, aripiprazole demonstrated a favourable safety and tolerability profile, with little propensity for weight gain or other adverse metabolic effects.